Title :

Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the cmwp-ebmt

Author(s) :

Gagelmann, Nico [Auteur]
Eikema, Diderik-Jan [Auteur]
De Wreede, Liesbeth C. [Auteur]
Rambaldi, Alessandro [Auteur]
Iacobelli, Simona [Auteur]
Koster, Linda [Auteur]
Caillot, Denis [Auteur]
Blaise, Didier [Auteur]
Remenyi, Peter [Auteur]
Bulabois, Claude-Éric [Auteur]
Université Grenoble Alpes [2016-2019] [UGA [2016-2019]]
Passweg, Jakob R. [Auteur]
Leleu, Xavier [Auteur]
Zver, Samo [Auteur]
Kobbe, Guido [Auteur]
Ljungman, Per [Auteur]
Chevallier, Patrice [Auteur]
Ringhoffer, Mark [Auteur]
Martin, Murray [Auteur]
Salmenniemi, Urpu [Auteur]
Poire, Xavier [Auteur]
Lenhoff, Stig [Auteur]
Pioltelli, Pietro [Auteur]
Mordini, Nicola [Auteur]
Delforge, Michel [Auteur]
Garderet, Laurent [Auteur]
Schonland, Stefan O. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Krger, Nicolaus [Auteur]

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant.

Volume number :

56

Pages :

210–217

Publication date :

2021-01

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) ...
Show more >We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation. 623 patients underwent either auto (n = 446), auto-auto (n = 105), or auto-allo (n = 72) between 2000 and 2015. 46% of patients had t(4;14), 45% had del(17p) while 9% were reported having both abnormalities. Five-year overall survival (OS) was 51% (95% confidence interval [CI], 45-58%) for single auto, 60% (95% CI, 49-72%) for auto-auto, and 67% (95% CI, 53-80%) for auto-allo (p = 0.187). Five-year progression-free survival (PFS) was 17% (95% CI, 12-22%), 33% (95% CI, 22-43%), and 34% (95% CI, 21-38%; p = 0.048). Five-year relapse rate was 82, 63, and 56%, while non-relapse mortality was 1, 4, and 10%. In multivariable analysis, in t(4;14) with single auto as reference, auto-auto (hazard ratio [HR], 0.44; p = 0.007) and auto-allo (HR, 0.45; p = 0.018) were associated with better PFS. In terms of t(4;14) and OS, auto-auto appeared to improve outcome compared with single auto (HR, 0.49; p = 0.096). In del(17p), outcome in PFS was similar between single auto and auto-auto, while auto-allo appeared to improve PFS (HR, 0.65; p = 0.097). No significant difference in OS was identified between the groups in patients with del(17p).Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2021-07-06T12:45:20Z
2024-01-18T13:52:44Z